Annual CFF
$646.40 M
+$478.45 M+284.87%
31 December 2023
Summary:
PTC Therapeutics annual cash flow from financing activities is currently $646.40 million, with the most recent change of +$478.45 million (+284.87%) on 31 December 2023. During the last 3 years, it has fallen by -$22.32 million (-3.34%). PTCT annual CFF is now -3.34% below its all-time high of $668.72 million, reached on 31 December 2020.PTCT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$17.63 M
-$264.11 M-107.15%
30 September 2024
Summary:
PTC Therapeutics quarterly cash flow from financing activities is currently -$17.63 million, with the most recent change of -$264.11 million (-107.15%) on 30 September 2024. Over the past year, it has dropped by -$20.99 million (-624.46%). PTCT quarterly CFF is now -102.74% below its all-time high of $643.05 million, reached on 30 September 2020.PTCT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$849.88 M
-$20.99 M-2.41%
30 September 2024
Summary:
PTC Therapeutics TTM cash flow from financing activities is currently $849.88 million, with the most recent change of -$20.99 million (-2.41%) on 30 September 2024. Over the past year, it has increased by +$521.05 million (+158.45%). PTCT TTM CFF is now -2.41% below its all-time high of $870.87 million, reached on 30 June 2024.PTCT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PTCT Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +284.9% | -624.5% | +158.4% |
| 3 y3 years | -3.3% | -692.3% | +1401.2% |
| 5 y5 years | +391.3% | -104.6% | +38.3% |
PTCT Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -3.3% | +2996.2% | -102.8% | +87.4% | -2.4% | +750.7% |
| 5 y | 5 years | -3.3% | +2996.2% | -102.7% | +87.4% | -2.4% | +750.7% |
| alltime | all time | -3.3% | +9103.2% | -102.7% | +87.4% | -2.4% | +750.7% |
PTC Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$17.63 M(-107.2%) | $849.88 M(-2.4%) |
| June 2024 | - | $246.48 M(>+9900.0%) | $870.87 M(+35.5%) |
| Mar 2024 | - | $540.00 K(-99.9%) | $642.85 M(-0.5%) |
| Dec 2023 | $646.40 M(+284.9%) | $620.49 M(>+9900.0%) | $646.40 M(+96.6%) |
| Sept 2023 | - | $3.36 M(-81.8%) | $328.83 M(+77.3%) |
| June 2023 | - | $18.46 M(+350.9%) | $185.48 M(+8.5%) |
| Mar 2023 | - | $4.09 M(-98.6%) | $170.88 M(+1.7%) |
| Dec 2022 | $167.95 M(+704.5%) | $302.92 M(-316.4%) | $167.95 M(-228.6%) |
| Sept 2022 | - | -$140.00 M(-3725.9%) | -$130.61 M(-1156.8%) |
| June 2022 | - | $3.86 M(+230.6%) | $12.36 M(-1.2%) |
| Mar 2022 | - | $1.17 M(-73.2%) | $12.51 M(-40.1%) |
| Dec 2021 | $20.88 M(-96.9%) | $4.35 M(+46.3%) | $20.88 M(-63.1%) |
| Sept 2021 | - | $2.98 M(-25.9%) | $56.61 M(-91.9%) |
| June 2021 | - | $4.02 M(-57.9%) | $696.69 M(+5.6%) |
| Mar 2021 | - | $9.53 M(-76.2%) | $659.76 M(-1.3%) |
| Dec 2020 | $668.72 M(+9.1%) | $40.09 M(-93.8%) | $668.72 M(+6.0%) |
| Sept 2020 | - | $643.05 M(-2053.5%) | $630.91 M(+70.4%) |
| June 2020 | - | -$32.92 M(-278.0%) | $370.21 M(-8.8%) |
| Mar 2020 | - | $18.49 M(+709.5%) | $405.98 M(-33.8%) |
| Dec 2019 | $613.21 M(+366.1%) | $2.28 M(-99.4%) | $613.21 M(-0.2%) |
| Sept 2019 | - | $382.35 M(>+9900.0%) | $614.65 M(+158.9%) |
| June 2019 | - | $2.85 M(-98.7%) | $237.38 M(-33.4%) |
| Mar 2019 | - | $225.72 M(+5958.0%) | $356.16 M(+170.7%) |
| Dec 2018 | $131.57 M | $3.73 M(-26.7%) | $131.57 M(+1.4%) |
| Sept 2018 | - | $5.08 M(-95.8%) | $129.70 M(+2.7%) |
| June 2018 | - | $121.63 M(>+9900.0%) | $126.32 M(+182.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | $1.14 M(-38.6%) | $44.69 M(+1.1%) |
| Dec 2017 | $44.22 M(+4468.0%) | $1.85 M(+8.4%) | $44.22 M(+4.3%) |
| Sept 2017 | - | $1.71 M(-95.7%) | $42.41 M(+2.0%) |
| June 2017 | - | $40.00 M(+5932.7%) | $41.59 M(+2504.5%) |
| Mar 2017 | - | $663.00 K(+1478.6%) | $1.60 M(+65.0%) |
| Dec 2016 | $968.00 K(-99.4%) | $42.00 K(-95.3%) | $968.00 K(+2.1%) |
| Sept 2016 | - | $892.00 K(>+9900.0%) | $948.00 K(-99.4%) |
| June 2016 | - | $0.00(-100.0%) | $146.02 M(-3.3%) |
| Mar 2016 | - | $34.00 K(+54.5%) | $151.08 M(-1.9%) |
| Dec 2015 | $154.06 M(-35.0%) | $22.00 K(-100.0%) | $154.06 M(-43.5%) |
| Sept 2015 | - | $145.97 M(+2788.7%) | $272.44 M(+114.8%) |
| June 2015 | - | $5.05 M(+67.4%) | $126.83 M(+4.0%) |
| Mar 2015 | - | $3.02 M(-97.5%) | $122.00 M(-48.6%) |
| Dec 2014 | $237.13 M(+26.5%) | $118.40 M(>+9900.0%) | $237.13 M(+99.8%) |
| Sept 2014 | - | $359.00 K(+64.7%) | $118.69 M(+2.8%) |
| June 2014 | - | $218.00 K(-99.8%) | $115.47 M(-53.8%) |
| Mar 2014 | - | $118.15 M(<-9900.0%) | $250.20 M(+33.5%) |
| Dec 2013 | $187.44 M(+736.4%) | -$36.00 K(-98.7%) | $187.44 M(+0.4%) |
| Sept 2013 | - | -$2.86 M(-102.1%) | $186.77 M(-0.7%) |
| June 2013 | - | $134.94 M(+143.6%) | $188.05 M(+134.7%) |
| Mar 2013 | - | $55.39 M(-7972.2%) | $80.13 M(+257.5%) |
| Dec 2012 | $22.41 M(-412.1%) | -$703.60 K(-55.4%) | $22.41 M(-3.0%) |
| Sept 2012 | - | -$1.58 M(-105.8%) | $23.11 M(-6.4%) |
| June 2012 | - | $27.02 M(-1259.5%) | $24.69 M(-1159.5%) |
| Mar 2012 | - | -$2.33 M | -$2.33 M |
| Dec 2011 | -$7.18 M | - | - |
FAQ
- What is PTC Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for PTC Therapeutics?
- What is PTC Therapeutics annual CFF year-on-year change?
- What is PTC Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for PTC Therapeutics?
- What is PTC Therapeutics quarterly CFF year-on-year change?
- What is PTC Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for PTC Therapeutics?
- What is PTC Therapeutics TTM CFF year-on-year change?
What is PTC Therapeutics annual cash flow from financing activities?
The current annual CFF of PTCT is $646.40 M
What is the all time high annual CFF for PTC Therapeutics?
PTC Therapeutics all-time high annual cash flow from financing activities is $668.72 M
What is PTC Therapeutics annual CFF year-on-year change?
Over the past year, PTCT annual cash flow from financing activities has changed by +$478.45 M (+284.87%)
What is PTC Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of PTCT is -$17.63 M
What is the all time high quarterly CFF for PTC Therapeutics?
PTC Therapeutics all-time high quarterly cash flow from financing activities is $643.05 M
What is PTC Therapeutics quarterly CFF year-on-year change?
Over the past year, PTCT quarterly cash flow from financing activities has changed by -$20.99 M (-624.46%)
What is PTC Therapeutics TTM cash flow from financing activities?
The current TTM CFF of PTCT is $849.88 M
What is the all time high TTM CFF for PTC Therapeutics?
PTC Therapeutics all-time high TTM cash flow from financing activities is $870.87 M
What is PTC Therapeutics TTM CFF year-on-year change?
Over the past year, PTCT TTM cash flow from financing activities has changed by +$521.05 M (+158.45%)